🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP).

How is structured, analyzable, real-world data transforming healthcare and medicine? In the latest episode of our podcast, TechBio Talks, host Najat Khan, PhD, talks to Amy Abernethy, MD, PhD, cofounder of Highlander Health. Amy is a physician, innovator, and executive who has

Replay Robinhood Presents: YES/NO? Yes.

🎁 It’s that time of year… time for Recursion Wrapped! ➡️ We’re reliving some of our favorite moments from 2025, including: 🔔 Ringing the Nasdaq bell 💻 Releasing Boltz-2 🎯 Reaching a 4th milestone with @sanofi 🎙️ Launching a podcast - TechBio Talks 🗺️ Announcing the

Earlier this week Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP). This data offers new hope for patients living with this relentlessly

Today we announced positive Phase 1b/2 results from our ongoing TUPELO trial evaluating REC-4881 in patients with familial adenomatous polyposis (FAP) – a rare, inherited disease with no approved pharmacologic treatments. Treatment with REC-4881 demonstrated rapid and durable

Join us today at 8am ET / 6am MT / 1pm BST for a webinar where we'll share updated clinical data from our ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP).

https://t.co/8PfcEZBWQs

Did you know? Rio Grande LNG has made ~$950,000 in charitable donations focused on community development and supporting 60+ local organizations.

“Where Innovation Meets Hope.” Tonight – Dec. 3, at 7pm ET – tune in to the @TEDx Tribeca livestream and hear from incoming CEO and President Najat Khan, PhD along with other leaders and visionaries, including T. Alexander Puutio, PhD; Jen Chiang; Yuval Ariav; Frank McCourt;

🔹 The advantages of a hybrid computing approach. Recently, CTO @bmabey spoke with Matt Marshall at a @VentureBeat AI Impact Series event about the advantages of a hybrid on-prem / cloud approach to computing in order to generate massive datasets, train AI models, and scale

🔹 New data readout coming. Join us for a webinar on Dec. 8, 8:00 am ET / 6:00 am MT / 1:00 pm GMT where we’ll share updated clinical data from our ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP). REC-4881 is a potentially first-in-disease

🚀 Want to work on the cutting edge of AI drug discovery? We’re looking for an Associate Principal of TechBio Discovery Biology in our Salt Lake City or New York City office. ✨ About the role: ▪️ You’ll be working at the intersection of technology and biology, and play a

Powerwall delivers backup you can count on. Stay powered even when storms hit.

In a new story in @statnews, incoming CEO and President Najat Khan, PhD spoke to @DrewQJoseph about why she’s confident in building on the company's progress in Recursion’s next chapter. ▪️ On why she’s excited to lead. “Pairing ambition with discipline is very important. As

🚀 The energy and momentum happening around life sciences in London –  fueled by innovation and investment in AI – is undeniable. That momentum was on full display last week at the @Jefferies Global Healthcare Conference and London Life Sciences Week presentations and events.

🧠 How the Microglia Map will help guide new insights and therapeutic pathways for treating neurodegenerative diseases. In a new story in @Tech_Networks, incoming CEO and President Najat Khan, PhD shared insights into the creation of the Microglia Map in partnership with @Roche

Fantastic turnout for the BoltzGen seminar in London at Recursion's office last night! Huge thanks to everyone who joined, the energy in the room was great, and it’s inspiring to see many already testing new BoltzGen designs on real problems.

🎉 Incoming CEO Najat Khan was named one of 2025’s Fiercest Women in Life Sciences from @FiercePharma. Each year, the list celebrates women who are making a powerful impact across biopharma and medtech, and have strong track records in innovation, leadership, and mentorship.

Leveraging the power of patient data. On Wed., Nov. 19, 8am PT / 11am ET, join us for a live webinar with @TempusAI to discuss "A new era of biopharma R&D: The TechBio revolution – Realities and the next frontier." Panelists @donnella_hayley, VP of Frontier Research at